JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Lista de Ações・Charles River Laboratories International Inc

Search

Charles River Laboratories International Inc

Abrir

SetorSaúde

165.57 -0.4

Visão Geral

Variação de preço das ações

24h

Atual

Mín

164.7

Máximo

166.47

Indicadores-chave
By Trading Economics
Rendimento	-332M -277M
Vendas	-11M 994M
Margem de lucro	-27.816
Funcionários	18,300
EBITDA	730K 198M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+14.5% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	508M 8.4B
Abertura anterior	165.97
Fecho anterior	165.57

Sentimento de Notícias

By Acuity

8%

92%

7 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

117.16 / 144.77 Suporte e Resistência

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de mai. de 2026, 22:17 UTC

Ganhos

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 de mai. de 2026, 23:47 UTC

Ganhos

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 de mai. de 2026, 23:45 UTC

Ganhos

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 de mai. de 2026, 23:45 UTC

Ganhos

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 de mai. de 2026, 23:40 UTC

Conversa de Mercado

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 de mai. de 2026, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 de mai. de 2026, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 de mai. de 2026, 22:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 de mai. de 2026, 22:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 de mai. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 de mai. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 de mai. de 2026, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Shareholders to Own About 51% of Combined Company

4 de mai. de 2026, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Board Unanimously Endorsed, Supported Deal

4 de mai. de 2026, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Deal Unanimously Recommended by Vault Board

4 de mai. de 2026, 22:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 de mai. de 2026, 22:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis Resources to Acquire All Ordinary Shares in Vault

4 de mai. de 2026, 22:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Regis Resources, Vault Minerals Agree to Merger of Equals

4 de mai. de 2026, 22:37 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 de mai. de 2026, 22:26 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 de mai. de 2026, 22:02 UTC

Ganhos

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 de mai. de 2026, 22:00 UTC

Conversa de Mercado

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 de mai. de 2026, 21:52 UTC

Ganhos

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 de mai. de 2026, 21:50 UTC

Ganhos

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 de mai. de 2026, 21:50 UTC

Ganhos

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 de mai. de 2026, 21:49 UTC

Ganhos

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 de mai. de 2026, 21:44 UTC

Ganhos

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 de mai. de 2026, 21:44 UTC

Ganhos

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 de mai. de 2026, 21:43 UTC

Ganhos

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 de mai. de 2026, 21:41 UTC

Ganhos

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 de mai. de 2026, 21:40 UTC

Ganhos

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

14.5% parte superior

Previsão para 12 meses

Média 197.3 USD 14.5%

Máximo 235 USD

Mínimo 160 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

7

Comprar

4

Manter

0

Vender

Com base em 11 analistas que deram avaliações de ações para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Recent bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

7 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Outras ações do setor

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat